Skip to main content

21-09-2020 | Prostate cancer | Video

ESMO 2020 | Addition of ipatasertib to abiraterone benefits certain patients with metastatic CRPC

Christopher Sweeney reports on the IPATential150 trial demonstrating the potential of combining the AKT inhibitor ipatasertib with abiraterone in metastatic castration-resistant prostate cancer patients with PTEN loss (4:21).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.